Brief: Cardiff Oncology Announces Data From Phase 1B/2 Trial In Colorectal Cancer

Cardiff Oncology

08/09/2021 21:20

Sept 8 (Reuters) - Cardiff Oncology Inc  CRDF.O :
    * CARDIFF ONCOLOGY ANNOUNCES NEW DATA FROM PHASE 1B/2 TRIAL
IN
KRAS-MUTATED METASTATIC COLORECTAL CANCER SHOWING ROBUST
OBJECTIVE RESPONSE RATE AND PROGRESSION FREE SURVIVAL
    * CARDIFF ONCOLOGY INC - COMBINATION REGIMEN OF ONVANSERTIB
PLUS
FOLFIRI/BEVACIZUMAB IS WELL TOLERATED
    * CARDIFF ONCOLOGY -  42% PATIENTS TREATED PER PROTOCOL AT
RECOMMENDED PHASE 2 DOSE OF ONVANSERTIB 15 MG/M AS OF DATA
CUT-OFF ACHIEVED PARTIAL RESPONSE
    * CARDIFF ONCOLOGY INC - 38%PATIENTS EVALUABLE FOR RESPONSE
AS OF
DATA CUTOFF DATE ACROSS ALL DOSE LEVELS ACHIEVED A PR
    * CARDIFF ONCOLOGY INC - MPFS HAS NOT YET BEEN REACHED IN
PATIENTS
TREATED PER PROTOCOL AT RP2D

Source text for Eikon:  ID:nPn9CDMSPa 
Further company coverage:  CRDF.O 

 ((Reuters.Briefs@thomsonreuters.com;))